Introduction
The use of antibiotics, especially the excessive and indiscriminative use, both in medicine and veterinary science has contributed to the emergence of drug resistant organisms. Antimicrobial drug resistance constitutes a growing problem worldwide [1] . Infections caused by resistant pathogens result in increased mortality and morbidity among human and animal populations. In addition, pathogenic microorganisms, including Staphylococcus aureus, Streptococcus pneumoniae and Clostridium difficile, contribute to many hospital-acquired infections. Gram-negative bacteria are traditionally more difficult to destroy than Gram-positive bacteria as they contain an outer membrane that constitutes an extra barrier for antibacterial compounds. The latest reports from the American and European disease associations claim that there are only a few antibiotics in the clinical pipeline that are more effective in targeting Gramnegative bacteria than existing pharmaceuticals on the market [1] . In the surveillance report titled "Antimicrobial resistance surveillance in Europe" made by the European Centre for Disease Prevention and Control, the authors show a general, Europe-wide increase in antimicrobial resistance in Gram-negative pathogens (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa) [2] .
In this review, the authors will discuss the present status of bacterial resistance to antibiotics, especially of bacterial species that cause serious hospital and community-acquired infections. Furthermore, the review presents antibiotics that are currently on the market and summarizes novel promising discoveries in drug development. The authors will also refer to new antibacterial targets and other alternatives to antibiotics.
How antibiotics became outdated?
The lack of new and effective antibacterial compounds is due to several factors. First of all, it is difficult to find new antibacterial compounds with good pharmacological profiles and low toxicity for the host. Furthermore, from an economic point of view, pharmaceutical companies are more interested in developing drugs for chronic conditions than for short-term treatments. Moreover, it is preferable when antibiotics target multiple species. In addition, bacteria tend to develop resistance to antimicrobials which restricts their use and consequently causes drug sales decline [3] . Finally, the chemical structures of antibiotics, especially those derived from
Present state of antibacterials
The majority of antibiotics currently applied in medical therapy belong to drug classes discovered before 1970, during the "golden age" of drug discovery. Since that time, most accomplishments in drug development were based on improvements and modifications to already existing compounds, giving rise to more potent analogues with greater stability to bacterial resistance [3] . Currently, nearly all anti-Gram-positive compounds under development, or recently introduced on the market, are analogues of already existing molecules, especially certain β-lactams, like cephalosporins (e.g. ceftobiprole and ceftaroline) and quinolones, which were modified to target MRSA and are discussed below [11] .
Since 2000, more than 20 antibacterial compounds have been introduced to the market. Some of them derive from natural products and usually carry semisynthetic modifications, e.g. daptomycin (Table 1) .
Antibacterial compounds that are currently undergoing pre-clinical and clinical development (phase I, II, III) are listed in Table 2 . Newly designed, modified drugs, which have already been introduced on the market, as well as those undergoing clinical trials and their modes of action are presented below in detail.
Cephalosporins
Ceftobiprole, a new cephalosporin, is active against MRSA and penicillin-resistant streptococci [14] . This drug was first introduced in 2008 in Switzerland and Canada, later withdrawn (in 2010), and is currently in clinical trials (Basilea Pharmaceutica Ltd.) [www.clinicaltrials.gov, 13]. Ceftaroline, on the other hand, was approved by the U.S. Food and Drug Administration (FDA) for treatment of acute bacterial skin and skin structure infections (SSSI) and community-acquired pneumonia (CAP) [15] . It is a broad spectrum antibiotic with activity against MRSA and drug resistant S. pneumoniae [16] .
CXA-101 is a novel cephalosporin-ceftolozane, which displays potent activity against P. aeruginosa and appears to be stable against bacterial resistance mechanisms. Data shows that it can be a potent agent in the treatment of chronic respiratory infection caused by P. aeruginosa in cystic fibrosis [17] . CXA-201 (Cubist Pharmaceuticals) is a combination of ceftolozane and a β-lactamase inhibitor, tazobactam, that is currently in phase 3 clinical trials for the treatment of complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI). It is active against Gramnegative bacteria, including multidrug-resistant (MDR) P. aeruginosa [www.clinicaltrials.gov, 18].
TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, which combines the activities of a glycopeptide and β-lactam, is currently in clinical development (completed phase II, Theravance) [www.clinicaltrials.gov]. The major application of TD-1792 is in treatment of cSSSI [12] . It possesses potent activity against Grampositive bacteria, including methicillin-sensitive S. aureus (MSSA), MRSA and vancomycin-intermediate S. aureus (VISA). The unique chemical structure of TD-1792 causes bacterial susceptibility and probably will result in slower development of resistance [19] .
Carbapenems
Carbapenems can be divided into those that are active against P. aeruginosa (biapenem, doripenem, meropenem, razupenem) and those that are not (ertapenem, tebipenem pivoxil, ME1036). Biapenem was approved for use in Japan in 2002 and has a broad spectrum of activity against S. pneumoniae, MSSA, A. baumannii, ESBL-producing Enterobacteriaceae and moderate activity against P. aeruginosa [13, 15] . Doripenem is active in vitro against streptococci, MSSA, ESBL-producing Enterobacteriaceae, Acinetobacter spp. and Bacteroides fragilis. In comparison to another carbapenem (meropenem), doripenem is also more effective against P. aeruginosa [20] . Razupenem is also a novel 1β-methylcarbapenem which acts against MDR Gram-positive and Gram-negative bacteria, especially MRSA and vancomycin-resistant Enterococcus (VRE), and may be a promising candidate for the treatment of nosocomial infections. It has lower activity against P. aeruginosa than comparable carbapenems (imipenem, meropenem) [21] . Tebipenem pivoxil is a prodrug whose active metabolite was shown to kill various groups of bacteria, including penicillin-nonsusceptible S. pneumoniae. It shows potent activity against pathogens causing UTI and respiratory tract infections. This oral carbapenem may be a potential drug for treatment of persistent otitis media, upper respiratory infection and bacterial pneumonia in pediatric patients [22, 23] . ME1036 is carbapenem drug with strong antibacterial activity against penicillin-resistant S. pneumoniae, E. faecalis, Haemophilus influenzae and Enterobacteriaceae strains but is not active against P. aeruginosa isolates [12, 15, 24] . Finally, ertapenem, was approved by the FDA for treatment of IAI, cSSSI, cUTI, acute pelvic infections and CAP [25, 26] . [27] . Therefore, this compound may be complementary to carbapenems. In a study by Hofer et al., BAL30072 was combined with different carbapenems and synergistic antibacterial activity was observed against many Enterobacteriaceae and P. aeruginosa [28] .
Monobactams

β-lactams with β-lactamase inhibitors
Among the new MBL inhibitors currently under investigation are BAL30376 and ME1071. The first compound consists of two monobactam moieties and clavulanic acid. It is active against metallo-β-lactamase (MBL)-producing strains and isolates of Burkholderia cepacia and carbapenemase-producing A. baumannii, but KPC-producing strains are resistant [15, 29] . The second, ME1071, is a maleic acid derivative, non-β-lactam inhibitor, used in combination with β-lactams. It potentiates the activity of ceftazidime and carbapenems against MBL-producing P. aeruginosa and significantly lowers the MIC of biapenem in a concentration-dependent manner against MBLproducing P. aeruginosa [25, 30] .
Other non-β-lactam inhibitors of β-lactamases have been identified, e.g. avibactam (NXL104, Novexel/ AstraZeneca) and MK-7655 (Merck). These related molecules (with diazabicyclo structures) inhibit class A and class C enzymes, including extended-spectrum and KPC-type β-lactamases [3] . Moreover, avibactam in combination with ceftazidime displays in vitro antibacterial activity against P. aeruginosa isolates [31] . Cerexa is currently recruiting participants for phase I clinical trials of avibactam in combination with ceftaroline fosamil (www.clinicaltrials.gov). MK-7655 was combined with imipenem and tested against imipenem-resistant Gram-negative isolates in vitro. The MICs for the strains were reduced, suggesting a potent efficacy of these drugs in combination [www.clinicaltrials.gov, 32]. Both of the compounds seem to be a solution for carbapenem usage, due to their inhibition of β-lactamases, which destroy β-lactams.
Aminoglycosides
There are also some "next-generation" aminoglycosides in clinical development, e.g. plazomicin. Plazomicin (ACHN-490, Achaogen) in 2012 completed phase 2 clinical trials for the treatment of cUTI and acute pyelonephritis. Phase 1 studies carried earlier were aimed to determine drug safety, blood pharmacokinetics, and lung penetration as well as to evaluate the effect of plazomicin administered intravenously on the QT/QTc interval in healthy volunteers (www.clinicaltrials.gov).
Aminomethylcyclines
Omadacycline (PTK0796, Paratek Pharmaceuticals) is a new tetracycline-derived broad-spectrum antibiotic for treatment of complicated bacterial SSSI. It's chemical structure is based on minocycline. Omadacycline exhibits activity against both Gram-positive (MSSA and MRSA) and Gram-negative bacteria. It is also active against tetracycline-resistant pathogens. In phase 2 study, the safety and tolerability profile of omadacycline was comparable to that of linezolid. No drug-related serious side-effects were noted [33] . Unfortunately phase 3 clinical trials on omadacycline was terminated in 2013 (www.clinicaltrials.gov).
Glycylcyclines
Tigecycline, a member of the glycylcyclines and approved by the FDA in 2005, was developed to overcome the difficulties with resistance to tetracyclines (mainly ribosomal protection and drug efflux). It was approved for treatment of cSSSI, cIAI and CAP. It shows a broad spectrum of antimicrobial activity against MRSA, VRE and other MDR Gram-negative bacteria [www.fda.gov, 14,34].
Lipopeptides
MX-2401 is a new semi-synthetic calcium (Ca 2+ )-dependent lipopeptide antibiotic in pre-clinical development. It is active against various Gram-positive bacteria, including strains not susceptible to vancomycin, macrolides, penicillin, methicillin, gentamicin and others. Interestingly, it possesses a different mode of action than daptomycin, the first calcium-dependent lipopeptide drug compound developed. Its mechanism of action relies on inhibition of peptidoglycan synthesis by binding to a specific substrate (C 55 -P) involved in several biosynthetic pathways. This interaction causes inhibition of the cell wall precursor lipids I, II and the wall teichoic acid precursor, lipid III [35] .
Lipoglycopeptides
Among the recently introduced antibacterial compounds is telavancin (trade name Vabativ ® , Theravance, 2009). It is a lipoglycopeptide that exhibits dual mechanisms of action based on inhibition of bacterial peptidoglycan synthesis at the transglycosylase step and membrane depolarization [12, 13, 36] . Another lipoglycopeptide, dalbavancin (a second generation, semi-synthetic compound), is currently in clinical trials by Durata Therapeutics for intravenous administration to patients with acute bacterial SSSI caused by Gram-positive bacteria [www.clinicaltrials.gov]. The advantage of dalbavancin is its very long half-life (ranging from 149 to 250 h), which allows it to be administered once a week [37] .
Ketolides
Telithromycin ketolide is an erythromycin-derivative approved by the FDA in 2004 for CAP, acute bacterial exacerbations of chronic bronchitis (ABECB) and acute bacterial sinusitis [14,38, www.fda .gov]. It shows more potent activity in vitro in studies against macrolidesusceptible organisms than erythromycin. It also targets erythromycin-resistant pneumococci [39] . However, after approval of telithromycin, its alarming adverse events were noted, such as hepatotoxicity, myasthenia gravis exacerbation and vision disturbances. Therefore, telithromycin was withdrawn for treating ABECB and acute bacterial sinusitis [40] . Cethromycin (Advanced Life Sciences), another ketolide agent, was shown to target CAP while having a high safety profile. In a study by English et al., the clinical efficacy and safety was studied and confirmed in therapy of mild to moderate CAP in adults. The authors conclude that cethromycin can be a potent solution for outpatient treatment of CAP [14, 41] . A novel compound, solithromycin (CEM-101) is in the clinical pipeline (oral form in phase III, Cempra Pharmaceuticals) for the treatment of CAP [42] . This fluoroketolide is active against Neisseria gonorrhoeae isolates and its use in uncomplicated gonorrhea is also being studied in clinical trials (phase I) [www.clinicaltrials.gov, 43].
Oxazolidinones
Oxazolidinones (linezolid), a new class of antibiotics, which exhibit structures different from old, known drugs, were expected to bypass many resistance mechanisms that normally affect antibiotic activity. Linezolid has been on the market since 2000 as a drug active against MRSA and VRE strains. However, resistance to linezolid occurred very quickly in the presence of the cfr gene. Cfr is responsible for resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins and streptogramin A [44] . As a consequence new members of the oxazolidinones are being extensively studied, including radezolid (RX-1741, Rib X Pharmaceuticals), and tedizolid phosphate (TR-701, torezolid, Trius Therapeutics). Radezolid is in phase 2 clinical trials on patients with uncomplicated SSSI (www.clinicaltrials.gov). Tedizolid phosphate, a prodrug of tedizolid is in phase 3 clinical trials for treatment of SSSI and was determined to be 4 to 8-fold more active than linezolid against linezolid-susceptible and resistant staphylococcal and enterococcal strains [14, 45] .
Fluoroquinolones and compounds with anti-gyrase/topoisomerase activity
Another important group of antibacterials are the fluoroquinolones, which, as mentioned earlier, comprise mostly synthetic compounds. The list of the approved fluoroquinolones is included in Table 1 [47] . Another new compound is JNJ-Q2 (Furiex Pharmaceuticals), fluorinated 4-quinolone. It exhibited activity against S. pneumoniae and staphylococci, including MRSA and completed phase II clinical trials for the treatment of SSSI [48] .
There are also some pyrrolopyrimidine inhibitors of the bacterial topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE) under development (Trius Therapeutics). This dual targeting strategy, inhibiting ATPbinding sites of both GyrB and ParE, seems to be a novel mechanism of action. In a recent study by Trzoss et al. a series of pyrrolopyrimidine inhibitors was optimized to exhibit antibacterial activity against Gram-negative pathogens, including P. aeruginosa, A. baumannii, E. coli and potent activity against S. aureus [49] . PD 0305970 and PD 0326448 (quinazoline-2,4-diones) are both GyrB/ParE inhibitors which show activity against Gram-positive bacteria that frequently carry quinolone resistance mutations [50] . Pyrrolamides are novel DNA gyrase inhibitors. Recently, Eakin et al. described initial prototypes of pyrrolamides with in vitro antibacterial activity against Gram-positive bacteria and selected Gram-negative pathogens. These compounds target the ATP-binding site of GyrB [51] .
In another study a series of compounds based on imidazopyridine and triazolopyridine scaffolds were identified. They also act through inhibition of GyrB/ParE. They present activity mostly against Gram-positive bacteria (MSSA, MRSA, S. pneumoniae) [52] .
There is another group of compounds, heteroaryl isothiazolones (HITZs), which display antibacterial activity against Gram-positive bacteria, including MRSA. Their mode of action also relies on inhibition of DNA gyrase and topoisomerase IV. These compounds are superior to some of the fluoroquinolones, which are inactive against MRSA carrying mutations in topoisomerases [53] . One of them, ACH-702 (isothiazoloquinolone, Achillion Pharmaceuticals) displayed potent activity against antibiotic-resistant Gram-positive bacteria (including MRSA) in vitro and in vivo. Furthermore, it is also active against some Gram-negative bacteria (H. influenzae, Moraxella catarrhalis, and a Neisseria spp., with minor activity against Enterobacteriaceae) [54] . NXL101 is another dual inhibitor of the essential bacterial DNA replication enzymes DNA gyrase and topoisomerase IV (Novexel). NXL101 is a quinoline compound with antibacterial activity against Grampositive bacteria, including methicillin and fluoroquinoloneresistant strains [55] . All of the above described dual inhibitors of DNA gyrase and topoisomerase are promising drug candidates due to the fact that they are often active against fluoroquinolone-resistant strains and that resistance development to these compounds is unlikely to proceed rapidly. 
Pyrimidin-2-ones
Streptogramins
Among drugs currently in clinical trials is NXL-103, a semisynthetic streptogramin (combination of flopristin and linopristin), which can be used in the treatment of CAP and community-acquired or nosocomial MRSA, VRE infections, and acute bacterial SSSI [www.clinicaltrials.gov, 57]. NXL-103 was also shown to have activity against S. aureus in a biofilm model. Furthermore, in several in vitro assays it was up to four times more active (lower MIC values) than quinupristin/ dalfopristin, a parenterally administered streptogramin [57] . [14, 61] . Amixicile is a propylamine derivative of nitazoxanide with better solubility in water and efficacy against C. difficile in mouse infection models. Independent investigations have determined that nitazoxanide and amixicile are inhibitors of thiamine pyrophosphate (TPP) which is a vitamin cofactor of pyruvate: ferrodoxin oxidoreductase (PFOR). Interestingly, by inhibiting vitamin cofactor, and not the enzyme per se, these nitrothiazolides may avoid fast-developing resistance [62] .
Pleuromutilins
New targets
The goal of many scientists working on developing new antibacterial agents is discovering and designing drugs acting via novel mechanisms of action and directed against novel targets [63] . Recognized antibiotic targets include: cell wall biosynthesis, lytic enzymes, fatty acid biosynthesis, folic acid biosynthesis and cell division [64] . The majority of antibacterial compounds impair these processes or enzymes. Yet, it is highly possible that there are many more enzymes and/or structures in the bacterial cell that could constitute targets for antibacterial drug activity.
Antibacterial targets can generally be defined as bacteria enzymes that are essential for cell function but at the same time are distinct from related mammalian structures. Among the newly discovered targets is the histidine kinase/response regulator pair WalK/WalR. This two-component system is highly conserved and essential for low G + C Gram-positive bacteria (e.g. S. aureus, Bacillus subtilis and E. faecalis [65, 66] ), where it is necessary for bacterial cell wall metabolism and growth. Signermycin B was found to be an inhibitor of the histidine kinase WalK [67] .
Another prospective target, UDP-3-O-acyl-Nacetylglucosamine deacetylase (LpxC), is an enzyme involved in lipopolysaccharide biosynthesis (lipid A) in Gram-negative bacterial cells [15] . The Achaogen company has developed an LpxC inhibitor, ACHN-975. It is in phase 1 clinical trials for the treatment of MDR Pseudomonas spp. [www.clinicaltrials.gov].
Other potential targets for new antibacterials are peptide deformylase (PDF) and FtsZ, required for cell division in most bacteria [65] . After translational initiation, PDF catalyzes the hydrolytic removal of the N-terminal formyl group from nascent proteins, which are further processed along bacterial protein synthesis pathways. Actinonin and a novel compound, BB-3497, are both potent inhibitors of E. coli PDF [68] . FtsZ, a homolog of eukaryotic tubulin, has significant importance for bacterial cell replication [69] .
Lipid II is the antibacterial target of a number of drugs, including vancomycin, mannopeptimycins and plectasin. Mannopeptimycins inhibit peptidoglycan synthesis at the transglycosylation level by targeting the membrane-bound precursor lipid II. They show activity against MRSA, penicillin-resistant streptococci and moderate activity against VRE. Plectasin also binds to lipid II but possesses a rather low level of activity against staphylococci [4, 70] .
Homoserine transacetylase (HTA) plays an important role in the biosynthesis of methionine in various microorganisms (Gram-positive and Gramnegative bacteria and many fungi) and is essential for growth in Met-poor environments. The absence of this enzyme in humans makes it an attractive target for new antimicrobial agents. Recently, β-lactone natural products inhibiting HTA were described [71] .
Among the new classes of antimicrobials are compounds interacting with bacterial DNA. Bis-indole antibiotics, such as MBX1162, inhibit DNA and RNA synthesis. Data showed that MBX1162 is potent in vitro against MDR A. baumannii, ESBL-producing K. pneumoniae, VRE and MRSA [15, 72] . However, these types of compounds are usually highly cytotoxic to mammalian DNA, which may limit their usage.
A novel bacterial target is the E. coli primase enzyme. Bacterial primases are essential for DNA replication. Agarwal et al. identified compounds that exhibit primase inhibition in vitro and antibacterial activity [73] .
Prokaryotic zinc metalloproteins, such as carbonic anhydrase and histidinol dehydrogenase, have recently been taken into consideration as anti-Brucella targets. They are required for growth and/or virulence in several intracellular pathogenic species. Selective inhibitors of these bacterial enzymes are regarded as one potential new anti-Brucella therapy [74] .
β-ketoacyl synthases I/II (Fab F/B), key enzymes in the production of bacterial cell membrane fatty acids, are yet another example of antibacterial targets. A compound recently discovered by Merck, platensimycin, exhibits activity against Gram-positive bacteria and was shown to be a Fab F/B inhibitor [11, 75] . Another compound which inhibits fatty acid synthesis (Fabl inhibitor) is AFN-1252 (previously named API-1252, Affinium Pharmaceuticals), (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)- 
Alternatives to antibiotics
Innovative antibiotic substitutes, like bacteriophages (phages), antimicrobial peptides (AMPs) and monoclonal antibodies, have also been described. Clinical evidence shows that phages can be successfully applied in the treatment of infections caused by Grampositive and Gram-negative bacteria. Bacteriophages have been used in medicine since the beginning of the 20 th century [77, 78] . Their advantage is that they are high specific to a target bacterium and therefore will not affect the microbial flora of humans. Moreover, bacteriophages are harmless to human and animal cells [79] . One disadvantage to the use of bacteriophages is that massive bacterial lysis may lead to toxic shock. Moreover, systemic use of phages for treating patients is likely to be immunogenic and may induce neutralizing antibodies. Apart from human therapy, bacteriophages have also been evaluated for use in the poultry and cattle industries, aquaculture and sewage treatment [80, 81] .
AMPs are produced in different tissues by plants, animals, bacteria and fungi as innate immunity and host defense factors [82] . The antimicrobial peptides database (APD) currently contains 183 bacteriocins, 291 plant AMPs, and 1648 animal host defense peptides. APD contains peptides from various biological sources (bacteria, plant, animal, and human), and with various biological activities including antibacterial, antifungal, antiviral (including anti-HIV), anticancer, antiparasitic, insecticidal, spermicidal and chemotactic activity. It was established in 2003 and is expanding [83; http://aps.unmc.edu/AP/main.php].
AMPs play a crucial role in the human immune system. They usually destroy bacterial cells by interaction with and destabilization of bacterial membranes. The primary advantage of AMPs as antimicrobial agents is their broad spectrum of activity. A large variety of human proteins and peptides have antibacterial and antifungal activity (e.g. defensins, cathelicidins and histatins). Some of them also demonstrate antiviral and anticancer properties. The mode of action of defensins and cathelicidins is based on electrostatic binding of the cationic peptide to the outer surface of the pathogen, followed by insertion of the peptide into the cytoplasmic membrane, resulting in leakage of the cell contents into the extracellular medium. Histatins possess potent antifungal properties and some antibacterial activities [82, [84] [85] [86] . Antimicrobial peptides show promising antibacterial activities in vitro, however challenges remain regarding their in vivo application (including delivery form, toxicity, high cost of production and allergic side effects [87] ).
Bacteriocins are a group of AMPs produced by bacteria. They differ from antibiotics in several aspects. They are produced on the surface of ribosomes in microbial cells, while antibiotics are primarily secondary metabolites of the cell. Moreover, bacteriocins do not accumulate in tissues and can be effective against antibiotic-resistant pathogens [88, 89] . However, bacteriocins do not have as broad a spectrum of antibacterial activity as antibiotics. Among the newly described bacteriocins is L-1077, produced by Lactobacillus salivarius L-1077. MICs of this peptide determined against 33 Gram-negative and Grampositive bacterial isolates ranged from 0.09 to 1.5 µg/ml [88] .
Human lysozyme is a pivotal component of the innate immune system and can be applied as an antimicrobial peptide agent. It acts against both Gram-negative and Gram-positive bacteria, but is less effective against the former due to the presence of an outer membrane in these bacteria. Human lysozyme does not effectively eradicate bacteria during chronic conditions. Yet, application of recombinant forms of this enzyme as therapeutic agents can be a promising approach in combating drug-resistant bacteria. Gill et al. engineered the first lysozyme protein specifically designed to exhibit enhanced stability. This compound was active against Gram-negative (P. aeruginosa) and Gram-positive (Micrococcus luteus) bacteria and was found to be more efficient than the natural human lysozyme [90] .
Monoclonal antibodies (mAbs) have also been considered as potential agents in narrow-spectrum antibacterial therapy. The advantage of such therapy is a high degree of specificity against bacterial targets that do not possess human homologs. One example is the C. difficile mAb combination, MK-3415A and MK-6072 (Merck), currently undergoing phase 3 clinical trials [91, www.clinicaltrials.gov]. Several monoclonal antibodies that target different P. aeruginosa cell proteins (e.g. KB001-A, KaloBios Pharmaceuticals), are also in clinical development [11, www. clinicaltrials .gov]. KB001-A shows anti-infective and anti-inflammatory properties and is developed for the treatment of patients suffering from cystic fibrosis and those chronically infected with P. aeruginosa [92] . Although promising, at present there are no FDA-approved mAbs for treating bacterial infections, as their safety and action still needs to be investigated.
Attempts have also been made to combine antibiotics with other agents, such as natural bioactive substances, to enhance their antibacterial activity. Examples include associating conventional antibiotics (like ciprofloxacin, gentamicin, pristinamycin, cefixime) with thyme oils, or β-lactams with epigallocatechin gallate [93, 94] . Such combinations (antibiotic with natural extracts) may allow antibiotics to be used at a lower dose or reduced frequency of application, and thus decrease their toxicity and development of resistance. However, these applications need further investigation, as natural bioactive compounds can occasionally lower antibiotic activity or interact with them.
In addition to the development of novel antimicrobial compounds, the World Health Organization (WHO) has called for improved surveillance of antimicrobial resistance (AMR), the rational use of antibiotics in humans and animals, and better prevention and control of infections [95] . Effective surveillance requires strengthening the laboratory capacity for AMR detection, enabling a prompt flow of information from laboratories to prescribers and national/subnational policy-making authorities, and ensuring that the information is appropriately used [96] . Other important issues should also be monitored, like certified quality of the drug, regulating drug promotion and improving dispensing and access to antibiotics [97] .
WHO emphasizes the need for infection prevention and control (IPC) in all health facilities, addressing the essential components (infrastructure, organizational aspects, laboratory support, human resources, protocols and practices) and linking them to public health services. WHO also proposed the roles, responsibilities and activities of national authorities in implementing functioning IPC programs (e.g. IPC education in relation to AMR in medical and nursing studies). Some countries (Australia, Belgium, England, France, Malaysia) have successfully introduced national strategies to combat AMR. For example, media campaigns to decrease antibiotic usage, admission screening and isolation, and reporting of mandatory indicators in France caused a 41% reduction of MRSA infections [98] .
It is also essential to increase vaccine uptake (antipneumococcal, anti-meningococcal, anti-Haemophilus influenza, etc.), especially by those in high-risk groups. Vaccines and diagnostics play an important role in the rational use of antibiotics and in preventing infections. One of the WHO recommendations encourages cooperation between industry, government bodies and academic institutions in the search for new drugs and vaccines [99] .
Conclusions
The Infectious Diseases Society of America, in response to the continued increase in antimicrobial resistance, proposed the "10x20 Initiative", in which it calls for the development of 10 new, safe and effective antimicrobials by 2020 [100] . Antibiotic resistance is an international problem. MDR pathogens are responsible for healthcare associated infections. The present outlook in the antibacterial drug market is not satisfactory, despite many successes in the laboratory. Emergence of MDR bacteria creates the necessity to seek novel antibiotics with new modes of action, including antibacterial compounds with original chemical structures, as well as alternate drug targets. Compounds with dual modes of action are promising for antimicrobial therapy (e.g. inhibitors of gyrase/topoisomerase IV). In this review we list many chemical moieties that are currently under investigation. Clinical trials of the compounds mentioned are mostly directed to the therapy of SSSI, CAP, IAI, and UTI. In this work, we report on some alternatives to antibiotics, such as bacteriophages, antimicrobial peptides, monoclonal antibodies and natural oils. Unfortunately, these approaches still do not have broad application in medicine. The success of the next wave of antibiotics will also require changes in in law regulations, clinical domains and reimbursement of medical expenses, for which considerable challenges lie ahead [11] .
